Bristol-Myers Squibb Company
Carbohydrate content of CTLA4 molecules

Last updated:

Abstract:

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

Status:
Grant
Type:

Utility

Filling date:

23 Jul 2018

Issue date:

9 Mar 2021